Clinical Trials Logo

Other clinical trials

View clinical trials related to Other.

Filter by:

NCT ID: NCT04853095 Completed - Prostate Cancer Clinical Trials

Effect of Peritoneal Fixation on Lymphocele Formation

PerFix
Start date: December 1, 2019
Phase: N/A
Study type: Interventional

The PerFix Trial aims to compare the use of peritoneal fixation technique to standard of care (no fixation) during robot-assisted radical prostatectomy with extended pelvic lymph node dissection (RARP + eLND) for the prevention of symptomatic and radiologic lymphocele formation.

NCT ID: NCT04852679 Completed - Clinical trials for Gastroenteropancreatic Neuroendocrine Tumor

Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs

PALACE
Start date: May 24, 2021
Phase: Phase 3
Study type: Interventional

This study will be conducted to support the registration of the lanreotide Autogel 120 mg formulation in China for the treatment of GEP-NETs and treatment of clinical symptoms of NETs. The study will include a screening period of up to 4 weeks followed by a 48-week intervention period. After completion of the main study period, approximately five participants will continue in a self/partner injection cohort with lanreotide Autogel 120 mg every 28 days for 24 weeks.

NCT ID: NCT04851977 Completed - Clinical trials for Respiratory Syncytial Virus Infections

A First in Human Study to Evaluate the Safety and Immune Response to a Vaccine for the Treatment of a Respiratory Virus, When Administered Into the Arm in Healthy Adult Participants

Start date: October 16, 2018
Phase: Phase 1
Study type: Interventional

Advanced Vaccine Laboratories Pty Ltd is developing a recombinant Respiratory Syncytial Virus (rRSV) vaccine for the protection of children (6 months to 5 years old) and the elderly from RSV infection. Human RSV infects nearly all children by the age of two years, and it is a leading cause of severe lower respiratory tract (LRT) disease in both paediatric and elderly populations as well as in individuals was immune system is profoundly compromised.

NCT ID: NCT04851821 Completed - Clinical trials for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

The Effectiveness of Phytotherapy in SARS-COV2(COVID-19)

Quercetix
Start date: January 4, 2021
Phase: Phase 1
Study type: Interventional

Quercetin is one of the flavonoids. Quercetin as well as rutin are recognized to be among the most active of the flavonoids. It is to quercetin that several medicinal plants, including ginkgo and St. John's Wort, owe part of their therapeutic effects. Often combined with vitamin C in supplements, it improves absorption by the body and delays its elimination. Quercetin is extracted from a variety of plant sources, including the onion peel and seeds and pods of Dimorphandra mollis, a tree in the legume family native to South America. At present, there is no scientific data to demonstrate the effectiveness of herbal medicine, regardless of the plant, to prevent or treat COVID-19. On the other hand, some plant-based food supplements have anti-inflammatory or immunomodulatory properties that may disrupt inflammatory defense mechanisms useful in fighting infections, and in particular against COVID-19.

NCT ID: NCT04851574 Completed - Clinical trials for General Anesthetic Drug Adverse Reaction

PKPD of Rocuronium and Sugammadex Profile in Pediatric Patients

Start date: October 27, 2017
Phase:
Study type: Observational

The aim of the study is to assess the pharmacokinetic and pharmacodynamic properties of rocuronium and sugammadex and their clinical effect in the terms of both the relaxation of paralysed muscles (rocuronium) and the reversal of neuromuscular blockade (sugammadex) in children over 2 years of age undergoing general anesthesia for surgical procedures needing muscle relaxation for more than 30 minutes.

NCT ID: NCT04851314 Completed - Clinical trials for Anesthetic Gas Consumption and Cost-Effectiveness

Comparison of Different Ventilator and Vaporizer Technologies to Study Economic and Environmental Implications

Start date: February 14, 2018
Phase: N/A
Study type: Interventional

The purpose of this study is to test whether or not the use of a low volume ventilator in an anesthesia machine reduces anesthetic costs significantly as compared to other high volume machines. The study will compare the a low-flow anesthesia machine to a traditional anesthesia machine during routine elective general surgery in patients with ASA ratings of 1-2 under general anesthesia receiving standard care.

NCT ID: NCT04850794 Completed - Premature Birth Clinical Trials

Evaluation of an Interdisciplinary Decision Guide for Infant Feeding Assessment

Start date: July 14, 2021
Phase: N/A
Study type: Interventional

Preterm infants are at risk for feeding problems which can persist through early childhood. These feeding problems may include oral motor, sensory, digestive, nutritional, respiratory, and/or behavioral components. In North Carolina's early intervention program, speech pathologists or occupational therapists are responsible for completing feeding evaluations, and may not know when to refer infants out to medical specialists to address these other domains. This study will test a decision support tool in hypothetical feeding evaluation scenarios. The hypothetical scenarios will consist of real feeding videos of preterm infants who recently participated in a multidisciplinary feeding evaluation. Parent-reported outcomes of the infant's real evaluation will be compared to those of the speech pathologists and occupational therapists in our study who do, and do not, use the decision support tool. The investigators hypothesize that therapists with the tool will make recommendations that are closer to those of the multidisciplinary team, and that they will find the tool useful and easy to use. Due to recruitment limitations with families, the study was adapted in October, 2021 prior to enrollment of subjects to use case studies, rather than infant videos, as the hypothetical situation from which to test the tool. Therapists will then answer clinical questions without using the tool when viewing the first case study, and will use the tool to answer questions when viewing the second case study. Order of case study presentation will be randomized among participants.

NCT ID: NCT04849702 Completed - Clinical trials for Complication of Surgical Procedure

Comparison of the Clavien-Dindo and Comprehensive Complication Index

Start date: October 20, 2012
Phase:
Study type: Observational [Patient Registry]

Our aim was to compare 2 postoperative complication scoring systems in predicting length of hospital stay and in-hospital costs after colorectal resections.

NCT ID: NCT04849182 Completed - Clinical trials for Benign Paroxysmal Positional Vertigo (BPPV)

Vertistop® D and Vertistop® L in Preventing Recurrence of High-recurrence BPPV

Start date: December 4, 2018
Phase: N/A
Study type: Interventional

Randomized, 3-arm controlled clinical study, to evaluate the effectiveness of supplementation with Vertistop® D (food supplement containing alpha-lipoic acid at modified release, Carnosine and Zinc, Vitamin D and Vitamins B) and Vertistop® L (food supplement containing fast releasing alpha-lipoic acid, Carnosine, Zinc and Curcumin) in preventing recurrence of high-recurrence BPPV (Benign Paroxysmal Positional Vertigo)

NCT ID: NCT04848688 Completed - Clinical trials for Strongyloides Stercoralis Infection

Efficacy and Safety of Moxidectin Versus Ivermectin Against Strongyloides Stercoralis

StrongMoxi_KH
Start date: February 5, 2022
Phase: Phase 3
Study type: Interventional

The study is an extension to the study StrongMoxi NCT04056325 and entails modifications based on the outcome of NCT04056325 part A. The study is a phase 3, double-blinded and randomized clinical trial conducted in Cambodia. It aims at providing evidence on efficacy, safety and pharmacokinetic measures of 8 mg of moxidectin compared to 200 μg/kg ivermectin in adults infected with S. stercoralis. The efficacy of the treatment will be assessed by collecting three stool samples once per-treatment and once 21-28 days post-treatment. The stool samples will be analyzed by a quantitative duplicate Baermann assay.